Wall Street investors drove Insulet (NSDQ:PODD) shares up nearly 4% today ahead of the insulin management company’s 4th-quarter and full-year earnings statement.
Bedford, Mass.-based Insulet posted losses of $14.3 million, or 30 cents per share, on sales of $47.2 million for the 3 months ended Dec. 31, 2011, adding 70% to the top line and shaving 31.3 percent off of its losses, compared with the same period in 2010.
For the full year Insulet logged losses of $57.2 million, or $1.22 per share, on sales of $152.3 million. That’s a bottom-line improvement of 6.5% and a top-line gain of 57.0%.
“We are working closely with the U.S. Food & Drug Administration on the upcoming 510(k) clearance of the next-generation OmniPod. In anticipation, we are in production on the first of our next generation OmniPod manufacturing lines, and we expect the initial international shipments of next generation OmniPods to occur in the coming months,” president & CEO Duane DeSisto said in prepared remarks.”
Insulet said it expects to post sales of $210 million to $225 million this year, with operating losses ranging between $25 million to $35 million.
Guidance For the year ending December 31, 2012, the Company estimates that revenue will be in the range of $210 to $225 million. The Company expects an operating loss of $25 to $35 million for the year ending December 31, 2012. Operating losses for the just-ended year were $42.5 million.
PODD shares closed at $19.88 on Wall Street today, up 3.9%.